The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system—including psychiatric drugs—are assessed for whether that drug might cause suicidal ideation or behavior.
I have a question about the book:
‘CNS Clinical Trials - Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders’.
Fill in the form below.
We will respond as fast as possible.
